Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas
Molecules · 23.03.2023 · 28 (7) · 2890
DOI: 10.3390/molecules28072890 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 23.03.2023. Verfasst von Felix Neumaier und 2 weiteren Autor:innen. Beteiligte Einrichtung: Forschungszentrum Jülich GmbH, Institute of Neuroscience and Medicine, Nuclear Chemistry (INM-5), Wilhelm-Johnen-Str., 52428 Jülich, Germany. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioma. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Gliomas are the most common primary brain tumors in adults. A diffuse infiltrative growth pattern and high resistance to therapy make them largely incurable, but there are significant differences in the prognosis of patients with different subtypes of glioma. Mutations in isocitrate dehydrogenase (IDH) have been recognized as an important biomarker for glioma classification and a potential therapeutic target. However, current clinical methods for detecting mutated IDH (mIDH) require invasive tissue sampling and cannot be used for follow-up examinations or longitudinal studies. PET imaging could be a promising approach for non-invasive assessment of the IDH status in gliomas, owing to the availability of various mIDH-selective inhibitors as potential leads for the development of PET tracers. In the present review, we summarize the rationale for the development of mIDH-selective PET probes, describe their potential applications beyond the assessment of the IDH status and highlight potential challenges that may complicate tracer development. In addition, we compile the major chemical classes of mIDH-selective inhibitors that have been described to date and briefly consider possible strategies for radiolabeling of the most promising candidates. Where available, we also summarize previous studies with radiolabeled analogs of mIDH inhibitors and assess their suitability for PET imaging in gliomas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Forschungszentrum Jülich GmbH, Institute of Neuroscience and Medicine, Nuclear Chemistry (INM-5), Wilhelm-Johnen-Str., 52428 Jülich, Germany.
- Institute of Radiochemistry and Experimental Molecular Imaging, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.
ORCID-Profile: Felix Neumaier, Boris D Zlatopolskiy, Bernd Neumaier
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Neumaier, F., Zlatopolskiy, B. D., & Neumaier, B. (2023). Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas. Molecules, 28(7), 2890. https://doi.org/10.3390/molecules28072890
Vancouver
Neumaier F, Zlatopolskiy BD, Neumaier B. Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas. Molecules. 2023;28(7):2890. doi:10.3390/molecules28072890
BibTeX
@article{Neumaier2023,
author = {Neumaier, Felix and Zlatopolskiy, Boris D and Neumaier, Bernd},
title = {Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas},
journal = {Molecules},
year = {2023},
volume = {28},
number = {7},
pages = {2890},
doi = {10.3390/molecules28072890}
}
EUVIMED